Characteristics of real‐world metastatic non‐small cell lung cancer patients treated with nivolumab and pembrolizumab during the year following approval
Background Evidence from cancer clinical trials can be difficult to generalize to real‐world
patient populations, but can be complemented by real‐world evidence to optimize …
patient populations, but can be complemented by real‐world evidence to optimize …
Real‐world outcomes of patients with metastatic non‐small cell lung cancer treated with programmed cell death protein 1 inhibitors in the year following US regulatory …
Background Evidence from cancer clinical trials has strong internal validity but can be
difficult to generalize to real‐world patient populations. Here we analyzed real‐world …
difficult to generalize to real‐world patient populations. Here we analyzed real‐world …
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis
SJ Antonia, H Borghaei, SS Ramalingam… - The Lancet …, 2019 - thelancet.com
Background Phase 3 clinical data has shown higher proportions of patients with objective
response, longer response duration, and longer overall survival with nivolumab versus …
response, longer response duration, and longer overall survival with nivolumab versus …
[HTML][HTML] Two-year survival with nivolumab in previously treated advanced non–small-cell lung cancer: A real-world pooled analysis of patients from France, Germany …
D Debieuvre, RA Juergens, B Asselain… - Lung Cancer, 2021 - Elsevier
Objectives Immune checkpoint inhibitors have become the standard of care for metastatic
non–small-cell lung cancer (NSCLC) progressing during or after platinum-based …
non–small-cell lung cancer (NSCLC) progressing during or after platinum-based …
Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non–small-cell lung cancer in CheckMate 227
JR Brahmer, JS Lee, TE Ciuleanu… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE We present 5-year results from CheckMate 227 Part 1, in which nivolumab plus
ipilimumab improved overall survival (OS) versus chemotherapy in patients with metastatic …
ipilimumab improved overall survival (OS) versus chemotherapy in patients with metastatic …
Randomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC)
DR Spigel, M McLeod, MA Hussein… - Annals of …, 2017 - annalsofoncology.org
Background: Nivolumab, the anti-programmed death (PD)-1 antibody, has demonstrated
durable responses and survival benefit in pts with advanced NSCLC, with some pts …
durable responses and survival benefit in pts with advanced NSCLC, with some pts …
[HTML][HTML] First-line nivolumab in stage IV or recurrent non–small-cell lung cancer
DP Carbone, M Reck, L Paz-Ares… - … England Journal of …, 2017 - Mass Medical Soc
Background Nivolumab has been associated with longer overall survival than docetaxel
among patients with previously treated non–small-cell lung cancer (NSCLC). In an open …
among patients with previously treated non–small-cell lung cancer (NSCLC). In an open …
[HTML][HTML] Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis
H Borghaei, TE Ciuleanu, JS Lee, A Pluzanski… - Annals of …, 2023 - Elsevier
Background First-line nivolumab plus ipilimumab prolongs survival versus chemotherapy in
advanced non-small-cell lung cancer (NSCLC). We further characterized clinical benefit with …
advanced non-small-cell lung cancer (NSCLC). We further characterized clinical benefit with …
[HTML][HTML] IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer
O Molinier, B Besse, F Barlesi, C Audigier-Valette… - ESMO open, 2022 - Elsevier
Background Immunotherapy using inhibitors targeting immune checkpoint programmed cell
death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) is currently the standard of care …
death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) is currently the standard of care …
[HTML][HTML] Safety, efficacy, and patient-reported health-related quality of life and symptom burden with nivolumab in patients with advanced non–small cell lung cancer …
DR Spigel, M McCleod, RM Jotte, L Einhorn… - Journal of Thoracic …, 2019 - Elsevier
Abstract Introduction CheckMate 153 (NCT02066636) is a phase 3B/4 study assessing
nivolumab in previously treated patients with advanced NSCLC. Eligibility criteria allowed …
nivolumab in previously treated patients with advanced NSCLC. Eligibility criteria allowed …